Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
NCT01578278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 606
Last updated 2020-10-05
Summary
This is a clinical study to evaluate the safety and efficacy of a bepotastine besilate-corticosteroid combination nasal spray for the treatment of seasonal allergic rhinitis (SAR) in an open exposure study with subjects who have a demonstrated history of Mountain Cedar pollen allergy. The primary study objective is to assess the reduction from baseline in averaged morning (AM) and evening (PM) values of reflective total nasal symptom scores for each of 3 nasal sprays (bepotastine besilate-fluticasone propionate combination nasal spray, bepotastine besilate nasal spray, fluticasone propionate nasal spray) compared to placebo nasal spray. For enrolled subjects, the study will involve a 7-10 day run-in screening period dosing with placebo nasal spray and then a 14-day treatment period where subjects will dose twice a day with 1 of the 4 test agent nasal sprays and record reflective and instantaneous scores for both nasal and ocular symptoms prior to each dosing.
Conditions
- Seasonal Allergic Rhinitis
Interventions
- DRUG
-
Bepotastine besilate formulation
Nasal Spray
- DRUG
-
Fluticasone propionate
Nasal Spray
- DRUG
-
Bepotastine besilate-fluticasone propionate
Nasal Spray
- DRUG
-
Placebo Comparator
Nasal Spray
Sponsors & Collaborators
-
Bausch & Lomb Incorporated
lead INDUSTRY
Principal Investigators
-
Tim McNamara, PharmD · ISTA Pharmaceuticals, Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-12-31
- Primary Completion
- 2012-08-31
- Completion
- 2012-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
NCT01673659 ·Status: COMPLETED ·Phase: PHASE3
-
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
NCT01783548 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis
NCT02279563 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
NCT00854360 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
NCT00574379 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis
NCT00988247 ·Status: COMPLETED ·Phase: PHASE3
-
Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
NCT01697956 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
NCT01134705 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
NCT01024608 ·Status: COMPLETED ·Phase: PHASE3
-
PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg
NCT01897428 ·Status: COMPLETED ·Phase: PHASE1
-
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
NCT00659750 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis
NCT00407927 ·Status: COMPLETED ·Phase: PHASE2
-
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
NCT00574210 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
NCT01007721 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)
NCT00659048 ·Status: COMPLETED ·Phase: PHASE3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
NCT01307319 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
NCT05234580 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol
NCT01537692 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
NCT01451541 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects
NCT07345442 ·Status: COMPLETED ·Phase: PHASE1
-
Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis
NCT00940953 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
NCT00163488 ·Status: COMPLETED ·Phase: PHASE3
-
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
NCT01133626 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
NCT01378429 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
NCT00790023 ·Status: COMPLETED ·Phase: PHASE3